German biotech CatalYm raises €50 million for GDF-15 inhibitor immunotherapy
pharmaphorum
NOVEMBER 12, 2020
Founded in 2016 as a spin-out from Wuerzburg University, CatalYm’s lead molecule CTL-002 is designed to neutralise the tumour-produced protein GDF-15. High concentrations of the GDF-15 in serum and tumour-micro-environment help cancers to evade the immune system and are associated with resistance to current therapies.
Let's personalize your content